 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ITI-5000 / HLB Bio Group
A UNITE (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1346;
In this study, we developed an innovative saRNA vaccine (ITI-5000) encoding the tumor-associated antigens HERV-K and CT-83 to promote a balanced T cell response and hinder tumor progression...Ethics Approval This study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Immunomic Therapeutics, Inc. (ITI).